Virpax Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRPX research report →
Companywww.virpaxpharma.com
Virpax Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
- CEO
- Jatinder Dhaliwal
- IPO
- 2021
- Employees
- 2
- HQ
- Berwyn, PA, US
Price Chart
Valuation
- Market Cap
- $497
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2364.82%
- ROIC
- 1322.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,067,225 · 20.56%
- EPS
- $-70.91 · -446.72%
- Op Income
- $-12,079,935
- FCF YoY
- -169509.16%
Performance & Tape
- 52W High
- $0.48
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 2.56
- Avg Volume
- 451
Get TickerSpark's AI analysis on VRPX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 17, 24 | Panis Jaydriane | other | 0 |
| Nov 18, 24 | Chaudhry Usama | other | 0 |
| Nov 19, 24 | Randhawa Esha | other | 0 |
| Jul 5, 24 | Su Judy | other | 0 |
| Jul 5, 24 | Field Katharyn | other | 2,500 |
| Jul 5, 24 | Field Katharyn | other | 0 |
| Jul 5, 24 | Herman Gary L | other | 2,500 |
| Jul 5, 24 | Dhaliwal Jatinder | other | 2,500 |
| Jul 5, 24 | Herman Gary L | other | 0 |
| Jul 5, 24 | Dhaliwal Jatinder | other | 0 |
Our VRPX Coverage
We haven't published any research on VRPX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VRPX Report →